ImmuneOnco Biopharmaceuticals (Shanghai) Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China
Reuters
Oct 02
ImmuneOnco Biopharmaceuticals (Shanghai) Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China
**ImmuneOnco Biopharmaceuticals (Shanghai) Announces Phase III Trial Application for IMM2510 in Lung Cancer** ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced the submission of an application to begin Phase III clinical trials of its investigational drug IMM2510 (palverafusp α) for the treatment of immunotherapy-resistant non-small cell lung cancer (NSCLC) in China. The application was recently submitted to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) and targets different types of lung cancer. Data from a Phase I study presented at the 2025 World Conference on Lung Cancer showed promising results, with IMM2510 achieving a 35.3% objective response rate and a 76.5% disease control rate. Under a license and collaboration agreement, ImmuneOnco holds commercial rights for IMM2510 in Greater China, while Axion Bio, Inc. (a subsidiary of Instil Bio, Inc.) has exclusive rights to develop and commercialize the drug outside the region. No new grant or funding has been announced in connection with this regulatory milestone. The company cautions that successful marketing of IMM2510 is not guaranteed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.